Caris Life Sciences, Inc. (CAI)
Caris Life Sciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Irving, TX, US. The stock last traded at $22.27, down 3.74% on the session, giving a market capitalisation of $6.30B. On trailing twelve-month figures it carries a trailing P/E of 59.90, a net margin of 10.6%. Its beta of 0.68 implies it has historically moved less than the broad market.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Caris Life Sciences, Inc. is most often compared with the following Healthcare names: